Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?

被引:14
|
作者
Abas, Abdul Hawil [1 ]
Marfuah, Siti [1 ]
Idroes, Rinaldi [2 ]
Kusumawaty, Diah [3 ]
Fatimawali [4 ]
Park, Moon Nyeo [5 ]
Siyadatpanah, Abolghasem [6 ]
Alhumaydhi, Fahad A. [7 ]
Mahmud, Shafi [8 ]
Tallei, Trina Ekawati [1 ]
Bin Emran, Talha [9 ]
Kim, Bonglee [5 ]
机构
[1] Sam Ratulangi Univ, Fac Math & Nat Sci, Dept Biol, Manado 95115, North Sulawesi, Indonesia
[2] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Pharm, Banda Aceh 23111, Aceh, Indonesia
[3] Univ Pendidikan Indonesia, Fac Math & Nat Sci Educ, Dept Biol, Bandung 40154, West Java, Indonesia
[4] Sam Ratulangi Univ, Fac Math & Nat Sci, Pharm Study Program, Manado 95115, North Sulawesi, Indonesia
[5] Kyung Hee Univ, Coll Korean Med, Seoul 05253, South Korea
[6] Birjand Univ Med Sci, Ferdows Sch Paramed & Hlth, Birjand 9717853577, Iran
[7] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 52571, Saudi Arabia
[8] Australian Natl Univ, John Curtin Sch Med Res, Dept Genome Sci, Canberra, ACT 0200, Australia
[9] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh
来源
MOLECULES | 2022年 / 27卷 / 07期
基金
新加坡国家研究基金会;
关键词
COVID-19; SARS-CoV-2; Omicron; natural immunity; hybrid immunity; MAIN PROTEASE; TRANSMISSION; MECHANISMS; INFECTION; VACCINES; FUTURE; ORIGIN;
D O I
10.3390/molecules27072221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing, with no signs of abatement in sight. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of this pandemic and has claimed over 5 million lives, is still mutating, resulting in numerous variants. One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated. As a result, many believe that Omicron provides a natural vaccination, which is the first step toward ending the COVID-19 pandemic. Based on published research and scientific evidence, we review and discuss how the end of this pandemic is predicted to occur as a result of Omicron variants being surpassed in the community. In light of the findings of our research, we believe that it is most likely true that the Omicron variant is a natural way of vaccinating the masses and slowing the spread of this deadly pandemic. While the mutation that causes the Omicron variant is encouraging, subsequent mutations do not guarantee that the disease it causes will be less severe. As the virus continues to evolve, humans must constantly adapt by increasing their immunity through vaccination.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] COVID-19 severity from Omicron and Delta SARS-CoV-2 variants
    Wrenn, Jesse O.
    Pakala, Suman B.
    Vestal, Grant
    Shilts, Meghan H.
    Brown, Hunter M.
    Bowen, Sara M.
    Strickland, Britton A.
    Williams, Timothy
    Mallal, Simon A.
    Jones, Ian D.
    Schmitz, Jonathan E.
    Self, Wesley H.
    Das, Suman R.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (05) : 832 - 836
  • [42] Vaccine against COVID-19 or against SARS-CoV-2 infection?
    Rieske, Piotr
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2020, 7 (03) : 131 - 145
  • [43] Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 108
  • [44] SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model
    Na Yun Lee
    Youn Woo Lee
    Seung-Min Hong
    Dain On
    Gyeong Min Yoon
    See-He An
    Ki Taek Nam
    Jun-Young Seo
    Jeon-Soo Shin
    Yang-Kyu Choi
    Seung Hyun Oh
    Jun-Won Yun
    Ho Young Lee
    Kang-Seuk Choi
    Je Kyung Seong
    Jun Won Park
    Laboratory Animal Research, 39
  • [45] Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study
    Ogawa, Fumihiro
    Oi, Yasufumi
    Honzawa, Hiroshi
    Misawa, Naho
    Takeda, Tomoaki
    Kikuchi, Yushi M.
    Fukui, Ryosuke M.
    Tanaka, Katsushi M.
    Kano, Daiki
    Kato, Hideaki
    Abe, Takeru
    Takeuchi, Ichiro
    PLOS ONE, 2022, 17 (10):
  • [46] Viral dynamics of omicron BA.2.76 variant of SARS-CoV-2 in a cohort of COVID-19 patients
    Li, Kangguo
    Wang, Demeng
    Qu, Huimin
    Rui, Jia
    Abudunaibi, Buasiyamu
    Guo, Zhinan
    Wu, Sihan
    Abudurusuli, Guzainuer
    Yang, Zimei
    Fang, Kang
    Zhang, Yidun
    Su, Chenghao
    Chen, Tianmu
    JOURNAL OF INFECTION, 2023, 86 (02) : 181 - 184
  • [47] Analysis of SARS-CoV-2 vaccine against COVID-19
    Kazuyori, Taisuke
    Sato, Akihito
    Morimoto, Yasuhiro
    Ito, Akihiko
    Kuwano, Kazuyoshi
    RESPIROLOGY, 2023, 28 : 202 - 203
  • [48] Acute odynophagia: A new symptom of COVID-19 during the SARS-CoV-2 Omicron variant wave in Sweden
    Piersiala, Krzysztof
    Kakabas, Lara
    Bruckova, Anna
    Starkhammar, Magnus
    Cardell, Lars Olaf
    JOURNAL OF INTERNAL MEDICINE, 2022, 292 (01) : 154 - 161
  • [49] Forecasting COVID-19 infection trends and hospitalizations in Italy due to SARS-CoV-2 variant of concern Omicron
    Gerli, Alberto G.
    Centanni, Stefano
    Soriano, Joan B.
    Ancochea, Julio
    MINERVA RESPIRATORY MEDICINE, 2022, 61 (02): : 92 - 93
  • [50] SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model
    Lee, Na Yun
    Lee, Youn Woo
    Hong, Seung-Min
    On, Dain
    Yoon, Gyeong Min
    An, See-He
    Nam, Ki Taek
    Seo, Jun-Young
    Shin, Jeon-Soo
    Choi, Yang-Kyu
    Oh, Seung Hyun
    Yun, Jun-Won
    Lee, Ho Young
    Choi, Kang-Seuk
    Seong, Je Kyung
    Park, Jun Won
    LABORATORY ANIMAL RESEARCH, 2023, 39 (01)